What is the Japan Pharmaceutical Manufacturers Association (JPMA)?

The Pharmaceutical Manufacturers Association of Japan is a voluntary association of 68 R&D-oriented pharmaceutical companies (as of January 1, 2026).

Since its establishment in 1968, the association has continued to contribute to global healthcare through the development of innovative new ethical drugs under the motto of "realization of patient-participatory medicine".

The Pharmaceutical Manufacturers Association of Japan (PMAJ) is engaged in a multifaceted program of activities to solve various problems common to the pharmaceutical industry, to deepen understanding of pharmaceuticals, and to promote international collaboration. In particular, we are working for the sound development of the pharmaceutical industry by strengthening our policy formulation and advocacy activities, addressing internationalization, and reinforcing our public relations system.

The JPMA, together with thePharmaceutical Research and Manufacturers of America (PhRMA) and theEuropean Federation of Pharmaceutical Industries and Associations (EFPIA), is a major pharmaceutical organization in the global pharmaceutical market and a founding industry member of the International Conference on Harmonization of Pharmaceutical Regulations (ICH ), which aims to achieve international harmonization of pharmaceutical regulations. The ICH is a founding industry member of the International Conference on Harmonization of Pharmaceutical Regulations (ICH). It also leads the Asian Pharmaceutical Associations Coordinating Council (APAC ), whose mission is to "bring innovative medicines to the people of Asia as quickly as possible.

Furthermore, as a member association of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA ), the Pharmaceutical Manufacturers Association of Japan (PMAJ) addresses issues related to global health, including access to medicines and intellectual property rights, countermeasures against globally spread infectious diseases such as the new coronavirus infection (COVID -19), and efforts to address the Sustainable Development Goals (SDGs). The organization also addresses various issues related to global health, such as the new Coronavirus Infectious Disease (COVID-19) and other infectious diseases on a global scale.

While mutually exchanging information and collaborating with each member organization, we are developing global activities to contribute to the treatment of patients around the world.

Pharmaceutical Cooperative Guide 2025

Related Information

TOP